On September 14, 2017, Wilson Sonsini was named a winner in the "Equity Deal of the Year" category as part of the 2017 China Law & Practice Awards.

Wilson Sonsini was recognized for representing WuXi Biologics, a leading open-access R&D capability and biologics technology platform company, in its $510 million IPO and listing on the Hong Kong Stock Exchange in June 2017.

Recipients of this year's China Law & Practice Awards were selected from more than 800 individual nominations. In their selections of finalists and winners, editors focused on "innovation and excellence—factors that have become even more important this year as clients seek new ways of raising money, making investments, and capitalizing on rare and strategic opportunities."

Click here for more information.